



Clinical Trial Details (PDF Generation Date :- Thu, 17 Aug 2023 05:20:59 GMT)

CTRI Number	CTRI/2023/03/050470 [Registered on: 07/03/2023] - Trial Registered Prospectively	
Last Modified On	07/03/2023	
Post Graduate Thesis	No	
Type of Trial	Interventional	
Type of Study	Medical Device	
Study Design	Single Arm Study	
Public Title of Study	Borns Robotic Surgery System Clinical Study	
Scientific Title of Study	Pilot Study Clinical Trial to Evaluate the Safety and Efficacy of Robotic Surgery System for Minimum Access Surgical Procedures	
Secondary IDs if Any	Secondary ID	Identifier
	CI/MD/2023/000005	DCGI
	CTP-IND-20220924 (version: v1.0 date: 24/09/2022)	Protocol Number
Details of Principal Investigator or overall Trial Coordinator (multi-center study)	Details of Principal Investigator	
	Name	Dr Vivek Bindal
	Designation	Head of Department
	Affiliation	Max Super Speciality Hospital Vaishali
	Address	Max Super Speciality Hospital, Vaishali W-3, Sector-1, Vaishali, Ghaziabad 201012, Uttar Pradesh, India Ghaziabad UTTAR PRADESH 201012 India
	Phone	9999931958
	Fax	
	Email	bindal.vivek@gmail.com
Details Contact Person (Scientific Query)	Details Contact Person (Scientific Query)	
	Name	Dr Vivek Bindal
	Designation	Head of Department
	Affiliation	Max Super Speciality Hospital Vaishali
	Address	Max Super Speciality Hospital, Vaishali W-3, Sector-1, Vaishali, Ghaziabad 201012, Uttar Pradesh, India Ghaziabad UTTAR PRADESH 201012 India
	Phone	9999931958
	Fax	
	Email	bindal.vivek@gmail.com
Details Contact Person (Public Query)	Details Contact Person (Public Query)	
	Name	Pawan Sharma
	Designation	Assistant Manager
	Affiliation	Max Hospital Vaishali
	Address	Office of Research, Max Hospital Vaishali W-3, Sector-1, Vaishali, Ghaziabad, 201012, U.P. Ghaziabad UTTAR PRADESH 201012



	India			
Phone	91-7409382830			
Fax				
Email	Pawan.Sharma2@maxhealthcare.com			
Source of Monetary or Material Support	Source of Monetary or Material Support			
	> Max Hospital Vaishali			
Primary Sponsor	Primary Sponsor Details			
Name	Max Hospital Vaishali			
Address	Max Hospital Vaishali W-3, Sector-1, Vaishali, Ghaziabad, 201012, U.P.			
Type of Sponsor	Private hospital/clinic			
Details of Secondary Sponsor	Name	Address		
	Borns Medical Robotics Inc	6325 Tucker Dr, San Jose, CA 95129 USA		
Countries of Recruitment	List of Countries			
	India			
Sites of Study	Name of Principal Investigator	Name of Site	Site Address	Phone/Fax/Email
	Dr Vivek Bindal	Max Speciality Hospital Vaishali	Department, Institute of Minimal Access, Bariatric and Robotic Surgery. 4th Floor tower 1 Room No 4 , Max Hospital Vaishali (A Unit of crosslay remedies limited)W-3, Sector-1, Vaishali, Ghaziabad, 201012, U.P. Ghaziabad UTTAR PRADESH	91-99999-31958 bindal.vivek@gmail.com
Details of Ethics Committee	Name of Committee	Approval Status	Date of Approval	Is Independent Ethics Committee?
	IEC Max Super Speciality Hospital, Vaishali	Approved	12/12/2022	No
Regulatory Clearance Status from DCGI	Status	Date		
	Approved/Obtained	23/02/2023		
Health Condition / Problems Studied	Health Type	Condition		
	Patients	Diseases of the digestive system		
	Patients	Overweight, obesity and other hyperalimentation		
Intervention / Comparator Agent	Type	Name	Details	
	Intervention	BMR-5000 Surgical Robot	The main system includes Surgical Cart, Control Console, Lens Drive Robot, Tool Drive Robot, and Equipment Cabinet. The main system operates the robotic instrument to complete the operation. The intended use of the BMR-5000 Surgical Robot is for precise control of key technical operations such as tissue clipping, sharp	



		dissection, blunt dissection, tissue exposure, cutting, suturing, hemostasis, and digestive tract reconstruction in minimally invasive surgery.										
Comparator Agent	NIL	NIL										
Inclusion Criteria	<table border="1"> <thead> <tr> <th colspan="2">Inclusion Criteria</th> </tr> </thead> <tbody> <tr> <td>Age From</td> <td>18.00 Year(s)</td> </tr> <tr> <td>Age To</td> <td>75.00 Year(s)</td> </tr> <tr> <td>Gender</td> <td>Both</td> </tr> <tr> <td>Details</td> <td>Patients who meet the surgical indications and need minimally invasive cholecystectomy, appendectomy, abdominal hernia repair, bariatric or gastrointestinal surgery. Volunteered to participate in this trial and signed the informed consent.</td> </tr> </tbody> </table>		Inclusion Criteria		Age From	18.00 Year(s)	Age To	75.00 Year(s)	Gender	Both	Details	Patients who meet the surgical indications and need minimally invasive cholecystectomy, appendectomy, abdominal hernia repair, bariatric or gastrointestinal surgery. Volunteered to participate in this trial and signed the informed consent.
Inclusion Criteria												
Age From	18.00 Year(s)											
Age To	75.00 Year(s)											
Gender	Both											
Details	Patients who meet the surgical indications and need minimally invasive cholecystectomy, appendectomy, abdominal hernia repair, bariatric or gastrointestinal surgery. Volunteered to participate in this trial and signed the informed consent.											
Exclusion Criteria	<table border="1"> <thead> <tr> <th colspan="2">Exclusion Criteria</th> </tr> </thead> <tbody> <tr> <td>Details</td> <td> <ol style="list-style-type: none"> Those who cannot tolerate or establish pneumoperitoneum. Severe heart, lung, liver, and kidney disease who cannot tolerate surgery. Those who need emergency surgery due to illness. History of continuous systemic corticosteroid or immunosuppressive therapy within the past 1 mon. The patient is mentally incapable to understand the requirements and consequences of the study. Pregnant and lactating women. The patient is unwilling or unable to comply with the doctor orders. Those who have participated in clinical trials within the past three months. Extremes of age (Less than 18 years or more than 75 years) Other conditions deemed inappropriate by the PI and medical staff. </td> </tr> </tbody> </table>		Exclusion Criteria		Details	<ol style="list-style-type: none"> Those who cannot tolerate or establish pneumoperitoneum. Severe heart, lung, liver, and kidney disease who cannot tolerate surgery. Those who need emergency surgery due to illness. History of continuous systemic corticosteroid or immunosuppressive therapy within the past 1 mon. The patient is mentally incapable to understand the requirements and consequences of the study. Pregnant and lactating women. The patient is unwilling or unable to comply with the doctor orders. Those who have participated in clinical trials within the past three months. Extremes of age (Less than 18 years or more than 75 years) Other conditions deemed inappropriate by the PI and medical staff. 						
Exclusion Criteria												
Details	<ol style="list-style-type: none"> Those who cannot tolerate or establish pneumoperitoneum. Severe heart, lung, liver, and kidney disease who cannot tolerate surgery. Those who need emergency surgery due to illness. History of continuous systemic corticosteroid or immunosuppressive therapy within the past 1 mon. The patient is mentally incapable to understand the requirements and consequences of the study. Pregnant and lactating women. The patient is unwilling or unable to comply with the doctor orders. Those who have participated in clinical trials within the past three months. Extremes of age (Less than 18 years or more than 75 years) Other conditions deemed inappropriate by the PI and medical staff. 											
Method of Generating Random Sequence	Not Applicable											
Method of Concealment	Not Applicable											
Blinding/Masking	Not Applicable											
Primary Outcome	<table border="1"> <thead> <tr> <th>Outcome</th> <th>Timepoints</th> </tr> </thead> <tbody> <tr> <td>Incidence of adverse events, serious adverse events, and complications (i.e., surgery-related adverse events, device defects)</td> <td> Before surgery (Day -30) Operation period (Day 0) 24 hours after surgery Postoperative (Day 3) Postoperative (Day 7) After surgery (Day 14) Postoperative (Day 30) </td> </tr> <tr> <td>Surgical success rate, which is the rate between the cases completed without unplanned change in surgical treatment (such as conversion to conventional laparoscopic /open surgery) and the total number of cases.</td> <td></td> </tr> </tbody> </table>		Outcome	Timepoints	Incidence of adverse events, serious adverse events, and complications (i.e., surgery-related adverse events, device defects)	Before surgery (Day -30) Operation period (Day 0) 24 hours after surgery Postoperative (Day 3) Postoperative (Day 7) After surgery (Day 14) Postoperative (Day 30)	Surgical success rate, which is the rate between the cases completed without unplanned change in surgical treatment (such as conversion to conventional laparoscopic /open surgery) and the total number of cases.					
Outcome	Timepoints											
Incidence of adverse events, serious adverse events, and complications (i.e., surgery-related adverse events, device defects)	Before surgery (Day -30) Operation period (Day 0) 24 hours after surgery Postoperative (Day 3) Postoperative (Day 7) After surgery (Day 14) Postoperative (Day 30)											
Surgical success rate, which is the rate between the cases completed without unplanned change in surgical treatment (such as conversion to conventional laparoscopic /open surgery) and the total number of cases.												
Secondary Outcome	<table border="1"> <thead> <tr> <th>Outcome</th> <th>Timepoints</th> </tr> </thead> <tbody> <tr> <td>operation time, intraoperative blood loss, device performance, physical status score (ECOG), cost analysis, etc.</td> <td> Operation period (Day 0) 24 hours after surgery Postoperative (Day 3) Postoperative (Day 7) After surgery (Day 14) Postoperative (Day 30) </td> </tr> </tbody> </table>		Outcome	Timepoints	operation time, intraoperative blood loss, device performance, physical status score (ECOG), cost analysis, etc.	Operation period (Day 0) 24 hours after surgery Postoperative (Day 3) Postoperative (Day 7) After surgery (Day 14) Postoperative (Day 30)						
Outcome	Timepoints											
operation time, intraoperative blood loss, device performance, physical status score (ECOG), cost analysis, etc.	Operation period (Day 0) 24 hours after surgery Postoperative (Day 3) Postoperative (Day 7) After surgery (Day 14) Postoperative (Day 30)											
Target Sample Size	Total Sample Size=20 Sample Size from India=20 Final Enrollment numbers achieved (Total)= Applicable only for Completed/Terminated trials											



Phase of Trial	Final Enrollment numbers achieved (India) =Applicable only for Completed/Terminated trials
Date of First Enrollment (India)	N/A
Date of First Enrollment (Global)	10/03/2023
Estimated Duration of Trial	No Date Specified
Recruitment Status of Trial (Global)	Years=0 Months=2 Days=0
Recruitment Status of Trial (India)	Not Applicable
Publication Details	Not Yet Recruiting
Brief Summary	NIL
	<p>Trial Title - Pilot Study Clinical Trial to Evaluate the Safety and Efficacy of Robotic Surgery System for Minimum Access Surgical Procedures</p> <p>Design - This study applies a single-center, single-arm clinical trial design, to include 20 subjects. Subjects who met the inclusion criteria of this study will be enrolled in the study for surgical treatment using the device.</p> <p>Site - Max Super Speciality Hospital, Vaishali (A Unit of Crosslay Remedies Limited)</p> <p>Sample Size - 20 Cases and the specific procedures are Cholecystectomy (5 cases), appendectomy or abdominal hernia repair (5 cases), gastrointestinal surgery (10 cases) including, bariatric surgery, and gastrointestinal tumors surgery.</p> <p>Scope - Patients who meet the indications for general surgery and intend to undergo minimally invasive surgery. (Such as cholecystectomy, appendectomy or abdominal hernia repair, gastrointestinal tumor, etc.)</p> <p>Indications - This device is used for precise control of key technical operations such as tissue clipping, sharp dissection, blunt dissection, tissue level exposure, cutting, suturing, hemostasis, nerve exposure, and protection, and digestive tract reconstruction in minimally invasive surgery, and assists in the completion of general surgery Minimally invasive surgery, etc.</p> <p>Purpose - This clinical investigation plan specifies a Pilot Study Clinical Trial to evaluate the efficacy and safety of a laparoscopic robotic surgical system produced by Borna Medical Robotics Inc., for minimally invasive surgery operations. The main clinical safety and efficacy evaluation endpoint of this trial is defined as:</p> <p>Primary Safety Outcome - Incidence of adverse events, serious adverse events, and complications (i.e., surgery-related adverse events, device defects)</p> <p>Primary Efficacy Outcome - Rate of successful completion of robotic assisted surgery without unplanned conversion to laparoscopic/open surgery.</p> <p>Secondary Efficacy Evaluation - operation time, intraoperative blood loss, device performance, physical status score (ECOG), cost analysis, etc.</p>